Maravai LifeSciences (MRVI) announced that Carl Hull will retire from his position as executive chairman of the board and that the board of directors has unanimously elected R. Andrew Eckert to succeed him as chairman of the board, effective December 5. Carl Hull founded Maravai in 2014 and served as CEO, assuming the role of executive chairman in October 2022. Eckert is a senior adviser to Permira, a global private equity company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences downgraded to Sell from Neutral at Goldman Sachs
- Maravai Lifesciences initiated with a Peer Perform at Wolfe Research
- Maravai Lifesciences price target lowered to $7 from $10 at Morgan Stanley
- Nvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz
- Maravai Lifesciences price target lowered to $13 from $17 at RBC Capital